Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases

竹源生物制药公司完成近9000万美元A轮融资，推进免疫学和炎症性疾病的新一代双特异性抗体研究

BOSTON, February 14, 2025-- Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, today announced the successful completion of its oversubscribed Series A financing of approximately $90 million. The round was led by new investor RA Capital Management, with participation from new investors including Janus Henderson Investors, Redmile Group, Invus, and ADAR1 Capital Management.

波士顿，2025年2月14日——Bambusa Therapeutics, Inc.（Bambusa），一家致力于开发针对免疫和炎症（I&I）疾病的双特异性抗体的生物技术公司，今天宣布成功完成其超额认购的约9000万美元的A轮融资。本轮融资由新投资者RA Capital Management领投，其他新投资者包括Janus Henderson Investors、Redmile Group、Invus和ADAR1 Capital Management参与。

All existing investors also participated..

所有现有投资者也参与了。

The funding will support the advancement of Bambusa's lead programs through Phase I trials and drive further pipeline development. In conjunction with the financing, Dr. Derek DiRocco, Partner at RA Capital Management, will join Bambusa's Board of Directors.

这笔资金将支持Bambusa的主要项目推进至第一阶段试验，并推动进一步的管线开发。作为融资的一部分，RA Capital Management的合伙人Derek DiRocco博士将加入Bambusa董事会。

Shanshan Xu, M.D., Ph.D., CEO and Founder of Bambusa Therapeutics, commented:

徐珊珊，医学博士，哲学博士，竹子治疗公司首席执行官兼创始人评论道：

'At Bambusa, we have assembled a dynamic team of emerging biotech entrepreneurs driven by speed, agility, and scientific excellence. We are grateful for the trust our new and existing investors have placed in us as we rapidly advance our bispecific antibody pipeline into the clinic. This financing is a testament to our vision and execution, and we are eager to continue building momentum toward delivering transformative therapies to patients in need.'.

“在Bambusa，我们组建了一支充满活力的新兴生物技术企业家团队，他们以速度、敏捷性和科学卓越性为驱动力。我们感激新老投资者对我们的信任，因为我们正迅速将我们的双特异性抗体管道推进到临床阶段。这次融资证明了我们的愿景和执行力，我们渴望继续努力，为有需要的患者提供变革性的治疗方法。”

Derek DiRocco, Ph.D., Partner at RA Capital Management, commented: 'RA Capital is pleased to partner with the Bambusa Therapeutics team as they rapidly move multiple I&I assets into the clinic over the coming year. The next wave of therapeutics for patients with I&I disorders will be both more efficacious and convenient than currently available options.

德里克·迪鲁科（Derek DiRocco）博士，RA Capital Management的合伙人评论道：“RA Capital很高兴与Bambusa Therapeutics团队合作，因为他们将在未来一年内迅速将多个I&I资产引入临床。对于I&I疾病患者而言，下一波治疗药物将比现有选择更有效且更便捷。”

The Bambusa Therapeutics pipeline fits this profile, as their half-life extended bispecific antibodies were designed to target complementary disease-driving signaling pathways, affording the potential for a best-in-disease profile for patients.'.

Bambusa Therapeutics 的研发管线符合这一特性，因为它们的半衰期延长的双特异性抗体旨在靶向互补的疾病驱动信号通路，为患者提供了成为同类最佳治疗方案的潜力。

Building a Best-in-Disease Pipeline

构建一个疾病领域最佳的管线

Since its founding in May 2024, Bambusa has built a robust pipeline of long-acting bispecific antibodies, leveraging validated targets and biological synergy to create best-in-disease therapies for I&I indications. Two of Bambusa's four programs are on track to enter the clinic in Q1 2025 and mid-2025, respectively..

自2024年5月成立以来，Bambusa已建立了强大的长效双特异性抗体管线，利用经过验证的靶点和生物学协同作用，为I&I适应症开发最佳疾病治疗方案。Bambusa的四个项目中有两个分别计划在2025年第一季度和2025年年中进入临床阶段。

• BBT001, Bambusa's lead candidate, is a bispecific antibody incorporating a number of features intended to supplant the current standard of care for a range of dermatological conditions.

• BBT001是Bambusa的主要候选药物，是一种双特异性抗体，融合了多种特性，旨在取代当前一系列皮肤病学病症的标准治疗方法。

• BBT002 is a bispecific antibody created as a 'platform in a molecule' with applications across respiratory, dermatology, and gastroenterology indications.

• BBT002是一种双特异性抗体，被设计为“分子中的平台”，在呼吸系统、皮肤病学和胃肠病学领域有广泛应用。

• Bambusa's additional development candidates, BBT003 and BB004, also have best-in-disease potential in the inflammatory bowel diseases and rheumatological indications.

• Bambusa的其他开发候选药物BBT003和BB004在炎症性肠病和风湿病适应症中也具有同类最佳的潜力。

About Bambusa Therapeutics

关于竹子疗法

Bambusa Therapeutics is a rapidly growing biotechnology company specializing in developing transformative inflammatory and immunological therapeutics. Based in the vibrant Boston Seaport area, Bambusa's mission is to advance the field of immunology with cutting-edge solutions. For more information visit www.bambusatx.com..

竹子疗法是一家快速发展的生物技术公司，专注于开发变革性的炎症和免疫治疗药物。公司位于充满活力的波士顿海港区，竹子疗法的使命是通过尖端解决方案推动免疫学领域的发展。欲了解更多信息，请访问www.bambusatx.com。